MLN0905 is a potent and selective inhibitor of Aurora B kinase, an enzyme involved in cell division and chromosomal segregation. Its primary application lies in cancer research, particularly in the development of targeted therapies for various malignancies. By inhibiting Aurora B, MLN0905 disrupts proper mitotic progression, leading to polyploidy and eventual cell death in rapidly dividing tumor cells. This makes it a valuable tool in studying mitotic mechanisms and evaluating the therapeutic potential of Aurora kinase inhibition. It has shown preclinical activity against hematological cancers and solid tumors, supporting its investigation as an anticancer agent. Researchers use MLN0905 to explore combination therapies with other chemotherapeutics to enhance efficacy and overcome drug resistance.